Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT05741619

Long-term Follow up of Patient With Anti-GABAbr Antibodies Associated-encephalitis.

Conditions: Autoimmune Encephalitis

Sex: All
Ages: 18 Years – N/A
Enrollment: 70
Sponsor: Hospices Civils de Lyon

Location: France

Summary

First described in 2010, GABA-B-receptor antibodies-associated encephalitis is a disease with a severe vital and functional prognosis. Indeed, functional status is mostly altered by encephalitis and it induced consequences while vital status is mostly engaged by cancer very often associated in the course of the disease, mostly small-cell lung cancer (SCLC).While knowledge is growing on clinical features at each stage of the disease, long-term outcome data is still lacking even if known to be pejorative.In this study, we aimed to describe long-term follow up of all patients who were diagnosed a GABAb-receptor antibodies-associated encephalitis in the French Paraneoplastic Neurological Syndrome Reference Center until now.

Eligibility Criteria

Inclusion Criteria:encephalitis tested positive to GABAbr-antibodies after the examination of CSF samples tested for autoimmune encephalitis at the French Paraneoplastic Neurological Syndrome Reference Center from January 2011 to January 2022.Exclusion Criteria:tested positive to another onconeural antibody.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05741619). StuddyBuddy aggregates publicly available trial information.